An observational study in Liver Cancer and Liver Metastases, sponsored by Maastricht University Medical Center. Recruiting at 31 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Maastricht University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Liver Neoplasms with a site in Netherlands — 9 open to participants now, 10 under way, 1 of them phase 3. Liver Neoplasms · Netherlands.
Among the 27 studies in Liver Neoplasms with a site in Netherlands, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2021, is one of 10 observational ones, and was the 27th registered.
1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.
Browse Liver Neoplasms studies →9 of the 27 studies in Liver Neoplasms with a site in Netherlands are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in Netherlands, France
Ages 18+
Niek Wijnen · Sites in Netherlands
Ages 18+
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18–110
Academisch Ziekenhuis Maastricht · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 3
First in 2003; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 200 across 344 observational studies indexed under Liver Neoplasms.
Median enrollment 60 across the 17 interventional studies, 1,005 across the 10 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 27 have an industry lead sponsor. The 10 most frequent:
Maastricht University Medical Center is the lead sponsor of 854 studies on the registry; 114 are open to participants now.
Maastricht University Medical Center has 1 study filed under Liver Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Neoplasms with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06601231Erasmus Medical CenterTo Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance. | 2027-04-18 |
| NCT07312292Niek WijnenRadioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) | 2027-05-01 |
| NCT07717437Maastricht University Medical CenterDRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. | 2027-11-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 27 studies in Liver Neoplasms with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE. This collaborative registry focuses on identifying associations between baseline clinical/imaging parameters, clinical outcomes, and safety for patients undergoing PVE/HVE.
Retrospective and prospective
All patients with primarily unresectable / potentially resectable liver cancer or liver metastases, who are treated with combined embolization of both portal and hepatic veins (PVE/HVE) in order to increase future liver remnant before resection.
Inclusion Criteria:
This registry collects data on patients who have undergone combined portal and hepatic vein embolisation prior to major liver surgery.
Resectability three weeks after PVE/HVE and 5 years overall survival
Time frame: From enrolment until 5 year follow up
Number of complications during embolization
The number of complications occurring during liver embolization (e.g., spill to the future liver remnant).
Time frame: Perioperative
Kinetic Growth Rate [%/week]
Volumetric assessments are performed at baseline and three weeks after embolization. Changes in FLR volume will be standardized (sFLR) by calculating the ratio of the FLR to the Standardized Total Liver Volume (sTLV) using the Vauthey formula. The DH will be calculated as the percentage point difference in sFLR volume between baseline and three weeks after embolization. The KGR will then be derived from the DH, quantifying the weekly percentage volume increase observed between these measurements.
Time frame: 3 weeks after the embolization
Functional Growth Rate [%/week]
The Functional Growth Rate reflects the rate at which FLR function increases after embolization, as measured by hepatobiliary scintigraphy. FLR function is expressed in %/min/m2 at baseline and three weeks after embolization. The functional degree of hypertrophy (FDH-function) is the percentage point difference in FLR function between these time points, and the FGR is calculated by dividing the DH-function by the number of weeks elapsed.
Time frame: Three weeks after the embolization
90-day survival after embolization
90-day survival is defined as the proportion of patients alive at 90 days after liver embolization, serving as a standard measure of short-term postoperative outcome and surgical safety.
Time frame: 90 days post-embolization / post-resection
Number of complications during surgery
The number of complications occurring during liver surgery (e.g., excessive blood loss and vascular or biliary injury).
Time frame: Perioperative
90 day survival after resection
90-day survival is defined as the proportion of patients alive at 90 days after liver surgery, serving as a standard measure of short-term postoperative outcome and surgical safety.
Time frame: 90 days
Clinical resection rates
The clinical resection rate is defined as the proportion of patients who undergo liver resection among those who started embolization.
Time frame: Until MDT decision on resection (yes/no), approximately 3-6 weeks after the embolization
Number of salvage procedures
This outcome measure captures the proportion of patients in whom the FLR fails to reach a sufficient volume or function after the initial embolization procedure, and who therefore undergo an additional salvage intervention (e.g., repeat or completion embolization) to further promote FLR growth before resection can be considered
Time frame: Approximately 3-6 weeks after the embolization
Number of participants with disease recurrence
The proportion of patients who develop disease recurrence (locoregional or distant) during follow-up after liver resection.
Time frame: Until five years after the embolization/resection
Number of oncological interventions during follow up
The number of additional oncological interventions (e.g., chemotherapy, repeat liver resection, ablation, radiotherapy) administered to patients during follow-up
Time frame: Until five years after the embolization/resection
Started Mar 2021 (actual). Primary completion is estimated for Nov 2027, 80 months after the start.
Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 80 months is below that.
Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maastricht University Medical Center →